BNOX Company Profile and Key Details

NASDAQ : BNOX

Bionomics

$0.25

0.0111+4.59%

At Close 4:00 PM

Not Actively Trading

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Bionomics Limited (BNOX) stock surged +4.59%, trading at $0.25 on NASDAQ, up from the previous close of $0.24. The stock opened at $0.25, fluctuating between $0.24 and $0.29 in the recent session.

Stock Snapshot

0.242

Prev. Close

4.95M

Market Cap

0.2421

Day Low

-0.017674581005586592

P/E Ratio

-14.32

EPS (TTM)

-1.51

Cash Flow per Share

0.25

Open

19.58M

Number of Shares

0.29

Day High

74.19%

Free Float in %

2.09

Book Value

906.4K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Jan 21, 2025	3.13	3.28	3.09	3.24	34.78K
Jan 17, 2025	3.16	3.25	3.09	3.15	30.1K
Jan 16, 2025	3.13	3.19	3.00	3.01	24.47K
Jan 15, 2025	3.30	3.45	3.09	3.23	21.4K
Jan 14, 2025	3.15	3.30	3.07	3.20	18.3K
Jan 13, 2025	3.10	3.20	3.04	3.16	22.9K
Jan 10, 2025	3.04	3.39	3.04	3.20	43.75K
Jan 08, 2025	3.60	3.60	3.20	3.22	44.52K
Jan 07, 2025	3.81	3.94	3.29	3.57	53.66K
Jan 06, 2025	3.30	3.92	3.30	3.81	93.64K
Jan 03, 2025	3.05	3.41	2.95	3.40	95.19K
Jan 02, 2025	3.65	3.65	2.90	2.93	113.96K
Dec 31, 2024	3.83	3.92	3.40	3.43	145.68K
Dec 30, 2024	4.07	4.27	3.62	3.64	200.67K
Dec 27, 2024	4.08	5.85	3.65	4.03	940.73K
Dec 26, 2024	4.90	4.99	3.90	4.45	599.97K
Dec 24, 2024	10.20	10.50	3.75	6.63	1.18M
Dec 23, 2024	3.01	3.48	2.91	3.04	619.54K
Dec 20, 2024	3.01	3.20	2.77	2.91	52.1K
Dec 19, 2024	3.16	3.34	2.89	3.00	37.55K

Contact Details

Eastwood, SA 5063

Australia

https://www.bionomics.com.au 618 835 46100

About Company

Bionomics Limited, a clinical-stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers in Australia and the United States. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which has completed phase 2 clinical trial for the treatment of social anxiety disorder and post-traumatic stress disorder. It also develops BNC375, a small molecule therapeutics for the treatment of cognitive impairment in Alzheimer's disease; BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, a vascular disrupting agent, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer, and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. Bionomics Limited has a licensing agreement with Merck & Co., Inc. The company was incorporated in 1996 and is based in Eastwood, Australia.

Stock Peers

ARGX

5.7+0.73%

argenx SE$781.72 REGN

20.7+3.02%

Regeneron Pharmaceuticals, Inc.$707.06 UTHR

0.28+0.05%

United Therapeutics Corporation$571.35 MDGL

-1.19-0.23%

Madrigal Pharmaceuticals, Inc.$517.39 VRTX

4.14+0.98%

Vertex Pharmaceuticals Incorporated$427.38 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 PRAX

-4.36-1.35%

Praxis Precision Medicines, Inc.$318.83 ALNY

8.3+2.76%

Alnylam Pharmaceuticals, Inc.$309.49 KRYS

2.31+0.89%

Krystal Biotech, Inc.$262.26 LGND

4.59+2.04%

Ligand Pharmaceuticals Incorporated$229.45

Company Overview

Bionomics Limited (NASDAQ:BNOX) closed at $0.25 USD, gaining $0.01 (4.59%) from the previous close of $0.24. The stock is currently within 5% of its 52-week low $0.24 and $16.32. With a market capitalization of about $4.95 million, Bionomics Limited is classified as a micro-cap and shows lower-than-market volatility (beta ~-0.07). Key stats such as the average daily volume over the past year has been around 881.89 thousand shares, in line with its 52-week average. Headquartered in Eastwood, SA, Bionomics Limited operates in the Healthcare sector and the Biotechnology industry. Led by CEO Spyridon Papapetropoulos, the company employs approximately 8 people and listed since December 16, 2021. Bionomics Limited, a clinical-stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers in Australia and the United States.

Technical Performance

BNOX has shown weak momentum, losing -11.22% over the past week and -61.06% over the past quarter, though year-to-date performance is down -82.9%. Short-term trend indicators are bullishly aligned (SMA20 -10.99%, SMA50 -11.67%, SMA200 -61.32%). The stock’s 14-day RSI is 42.52 (neutral), while the ATR of 0.04 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -84.18% below its high and over 43.0% above its low.

Valuation Metrics

Bionomics Limited trades at a P/E ratio of -0.0, slightly below the S&P 500 average, with a price-to-sales ratio of -7.48 The P/FCF stands at 0.07, also above market averages.

Dividend & Fair Value

Bionomics Limited last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.77. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

Bionomics Limited generated EPS of -$0.94 over the past year. Five-year average earnings growth is 14.53%. The latest quarter delivered EPS of -$0.04. The next quarter is forecast at $nan. Next year's EPS is expected at -$37.51. Bionomics Limited earnings surprise history is a mixed track record. The quarter that ended September 30, 2024, missed forecasts by -96.24%. The prior quarter beat by 0.0%. Over the last six quarters, Apple has recorded several small beats. These include -14.88% in August 28, 2022.

Shareholding & Insider Activity

Bionomics Limited has 1.63 million shares outstanding. The public float is 2.61 billion shares, elevated short interest at 1.23% of float. This equals 190.27 thousand shares. The short ratio is 0.13 days.

Financial & Profitability Overview

Over the trailing twelve months, Bionomics generated $23.95M in revenue, or $14.76 per share. Gross margin was 95.76%, operating margin -7.21%, and net profit margin -2.36%. Returns are negative, with ROA at -0.00% and ROE at -0.00%.
On valuation metrics, Bionomics trades at a P/E of -0.00, P/S of -7.48 and P/B of 0.00. The current ratio is 9.04 and quick ratio is 9.04. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is -611.30 days , indicating it collects cash faster than it pays suppliers.

Quarterly Financial Highlights

For the quarter ended Jun 30, 2025, Bionomics posted revenue of $23.95M, down slightly from $0.00 in the prior quarter. Gross profit was $22.94M (margin 95.76%). Operating income was - $1.73M (margin -7.2%). Net income was- $565.77K (EPS - $0.23).
The company ended the quarter with $14.21B in cash and short-term investments, a total debt of $116.31M, and net debt of - $14.09B. Total assets were $28.59B, with equity of $19.00B. Financials further reflected stability, with operating cash flow of $77.23M, free cash flow of $77.23M, and capital expenditures of $0.00.

Price Forecast & Outlook

Our AI price prediction model suggests that Bionomics Limited stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 61.42%, with price expected at $5.23 by February 04, 2025, within a range of $3.95 to $6.54 3-Month Outlook: Projected rise of 300.93%, reaching $12.99 by April 08, 2025, with a range of $12.67 to $13.43. 1-Year Outlook: Projected gain of 107.72%, with price at $6.73 by January 08, 2026, within a range of $4.83 to $7.28.

Key Takeaways

Bionomics Limited (NASDAQ:BNOX) shares are down -82.9% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Bionomics Limited trading at a premium to the broader market with a P/E of -0.0. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $15.25, suggesting 370.68% upside. Our AI forecast model points to short-term strength (61.42% over two weeks), a medium-term rise (300.93% over three months), and a longer-term gain (107.72% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Bionomics Limited (BNOX) stock price?

Bionomics Limited (NASDAQ: BNOX) stock price is $0.25 in the last trading session. During the trading session, BNOX stock reached the peak price of $0.29 while $0.24 was the lowest point it dropped to. The percentage change in BNOX stock occurred in the recent session was 4.59% while the dollar amount for the price change in BNOX stock was $0.01.

BNOX's industry and sector of operation?

The NASDAQ listed BNOX is part of Biotechnology industry that operates in the broader Healthcare sector. Bionomics Limited designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of BNOX?

No Data

How BNOX did perform over past 52-week?

BNOX's closing price is 4.54% higher than its 52-week low of $0.24 where as its distance from 52-week high of $16.32 is -98.45%.

How many employees does BNOX have?

Number of BNOX employees currently stands at 8.

Link for BNOX official website?

Official Website of BNOX is: https://www.bionomics.com.au

How do I contact BNOX?

BNOX could be contacted at phone 618 835 46100 and can also be accessed through its website. BNOX operates from 200 Greenhill Road, Eastwood, SA 5063, Australia.

How many shares of BNOX are traded daily?

BNOX stock volume for the day was 906.4K shares. The average number of BNOX shares traded daily for last 3 months was 881.89K.

What is the market cap of BNOX currently?

The market value of BNOX currently stands at $4.95M with its latest stock price at $0.25 and 19.58M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	8
Beta	-0.07
Sales or Revenue	$23.95M
5Y Sales Change%	14,847.522%
Fiscal Year Ends	June
Sector	Healthcare
Industry	Biotechnology

BNOX Company Profile and Key Details

Bionomics

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Company Overview

Earnings & Analyst Outlook

Dividend & Fair Value

Shareholding & Insider Activity

Valuation Metrics

Financial & Profitability Overview

Quarterly Financial Highlights

Key Takeaways

Price Forecast & Outlook